新辅助免疫治疗联合化学治疗后食管癌微创术式选择

打开文本图片集

中图分类号 R616 R735.1 文献标识码 A文章编号 2096-7721（2025）06-0999-09

Minimally invasive surgery options for esophageal cancer following neoadjuvant immunotherapy combined with chemotherapy

TANG Muhu，XU Zhengchao， WANG Luming，ZHU Linhai， LIN Xu， WANG Yiqing，LYU Wang， YE Peng， HU Jian （DepartmentofThoracic Surgery，theFirstAfiliatedHospitalof Zhejiang University，Hangzhou31ooo3，China）

AbstractObjective：Tocomparethetherapeuticeficacyofrobot-asistedminimallyinvasiveesophagectomy（RAMIE）versusvideo assistedminimallinvasivesopagectomy（VAME）inesophagealcancerpatientshounderwentneoadjuvantimmunotherapycombined withchemotherapy.Methods： Clinicaldata fromesophagealcancerpatients whounderwentRAMIEor VAMIEfollowing neoadjuvant therapycombinedwithchemotherapywereretrospectivelyanalyzed.Operative time，postoperativecomplicationrates （particularly pulmonary inflammation），andoverallprognosis wereevaluated.Results：TheRAMIE groupshowedalongeroperativetiethan theVAMIE group，thoughthediferencewasnotstatisticallysignificant.Theoverallpostoperativecomplicationratewaslowerinthe RAMIE groupthanthat intheVAMIE group，withasignificantlyreduced incidenceofpulmonary inflammation（ P =0.020）.No significant diferencewasobseredinsurvivaloutcomesbetweenthetwogroups.Conclusion：Foresophagealcancerpatientsreceivednoadjuvant immunotherapyombiningithchemotherap，RAMEisasafeandeasibleinimallyvasiveapproach，whichhasaowerpostoative complication ratebut comparable survival benefits compared to VAMIE，particularly in pulmonary inflammation.

Key WordsEsophageal Cancer; Neoadjuvant Therapy; Surgical Method; Robot-assisted Surgery; Endoscopic Surgery

作为全球致命性极高的恶性肿瘤之一，食管癌（EsophagealCarcinoma，EC）在癌症相关死亡率中排名第六[。（剩余12852字）